Loading...
Loading...
APVO| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 123.0K |
| Gross Profit | -123.0K |
| Operating Expense | 6,561.0K |
| Operating I/L | -6,561.0K |
| Other Income/Expense | 227.0K |
| Interest Income | 0.0K |
| Pretax | -6,334.0K |
| Income Tax Expense | 162.6K |
| Net Income/Loss | -6,334.0K |
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in developing immunotherapeutic candidates for cancer treatment. Its lead clinical candidate, APVO436, is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, APVO603, and APVO442, all of which are bispecific antibody candidates targeting various cancer antigens. Aptevo also has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. The company generates revenue through the development and potential commercialization of its immunotherapeutic candidates for cancer treatment.
